JNJ

Q3 2025

Date: 2025-10-14Rank: #100Forward Promise: bullish

Johnson & Johnson reported strong Q3 2025 results, delivering operational sales growth of 5.4% to $24 billion, driven by a 5.3% increase in Innovative Medicine to $15 billion and 5.6% growth in MedTech to $8.4 billion. Adjusted EPS rose 15.7% year-over-year to $2.80, significantly outpacing the prior year's $1.11, which was impacted by a one-time charge. Growth was broad-based, with 11 brands achieving double-digit growth, including DARZALEX (+19.9%), TREMFYA (+40.1%), and SPRAVATO (+60.8%), successfully offsetting the steep decline in STELARA (-42%) due to loss of exclusivity. The company announced a strategic plan to separate its Orthopaedics business within 18-24 months to focus on higher-growth areas, and raised full-year 2025 sales guidance to a range of 4.8%-5.3% operational growth.

Bullishness Score

85.56

μ Mean

91.07

σ Uncertainty

1.84

Forward Promise

7.8

Management Tone

Management exhibited a high degree of confidence and assertiveness throughout the call, emphasizing a 'powerful new era of growth' and 'accelerated' momentum. The tone shifted from defensive in prior years regarding STELARA loss of exclusivity to offensive, highlighting the successful navigation of this headwind and the strength of the underlying portfolio. Executives were direct in their capital allocation strategy, explicitly stating they do not need large M&A to meet targets, and were forthcoming about the rationale and financial benefits of the Orthopaedics spin-off.

Confidence: HIGH — Management used definitive language ('unequivocally answered,' 'confident,' 'very bullish') and provided specific forward-looking data points that exceeded consensus expectations, indicating strong visibility into future performance.

Strategic Signals

Management is aggressively pivoting the portfolio towards higher-growth, higher-margin markets by announcing the separation of the Orthopaedics business. This move, expected to be completed in 18-24 months, allows J&J to concentrate resources on six priority areas: oncology, immunology, neuroscience, cardiovascular, surgery, and vision. The company projects this separation will increase MedTech's top-line growth and operating margins by at least 75 basis points, signaling a commitment to capital efficiency and shareholder value creation.

The Innovative Medicine segment is demonstrating robust resilience and diversification, successfully navigating the STELARA cliff. Excluding STELARA, the pharmaceutical business grew 16% in Q3, driven by double-digit growth in 11 key brands. The strategic focus on immunology is shifting from STELARA to TREMFYA, which grew 40% and is positioned as a potential $10 billion asset, supported by new subcutaneous formulations and IBD indications.

J&J is leveraging a 'scientific expertise' M&A strategy, prioritizing smaller, tuck-in deals that utilize internal development capabilities rather than large, transformative acquisitions. The success of Inlexo (acquired for ~$200 million and projected to be a $5 billion blockbuster) exemplifies this approach. The company remains disciplined on capital allocation, prioritizing internal pipeline investment over 'desperate' large deals.

The MedTech sector is accelerating, driven by recent acquisitions like Shockwave (+20.9% growth) and Abiomed (+15.6% growth). Management highlighted specific clinical wins, such as the DANGER SOX study showing Impella's mortality benefit, which strengthens the competitive moat. The upcoming submission of the Ottava robotic surgical system in 2026 signals a strategic intent to compete in high-growth surgical markets.

Management provided specific preliminary guidance for 2026 that exceeds current Street consensus, projecting revenue growth above 5% versus the consensus of 4.6%. This visibility is supported by a deep pipeline of near-term catalysts, including the launch of Inlexo in bladder cancer, subcutaneous Rybrevant in lung cancer, and the potential approval of icotrokintra for psoriasis.

Key Metrics

Operational Sales Growth5.4%YoY

Innovative Medicine Sales$15.0B+5.3% Operational

MedTech Sales$8.4B+5.6% Operational

Adjusted EPS$2.80+15.7% YoY

TREMFYA Growth40.1%Operational

STELARA Growth-42%YoY

DARZALEX Growth19.9%Operational

SPRAVATO Growth60.8%Operational

MedTech Operating Margin21.0%-310 bps YoY

Guidance

2025 Operational Sales Growth: 4.8% to 5.3% (Raised)

2025 Reported Sales Growth: 5.4% to 5.9%

2025 Adjusted EPS: $10.80 to $10.90 (Reaffirmed)

2026 Sales Growth (Preliminary): >5% (vs Consensus 4.6%)

Orthopaedics Separation: Targeting completion in 18-24 months

Bottom Line

Price Target: N/A

Johnson & Johnson has successfully turned a corner, transforming from a company facing a patent cliff into a growth engine. Q3 results proved the resilience of the Innovative Medicine portfolio, which grew 5.3% despite a massive headwind from STELARA, driven by double-digit growth in oncology and immunology. The strategic decision to spin off Orthopaedics sharpens the company's focus on high-growth, high-margin markets like cardiovascular and robotics, while unlocking value for shareholders. Management's confidence is palpable, underscored by their willingness to guide 2026 growth above consensus estimates. With a deep pipeline of near-term catalysts, including Inlexo and Icotrokintra, and a disciplined capital allocation strategy prioritizing internal R&D, J&J is well-positioned for sustained market outperformance.

Forward Promise

Overall: 7.8 · bullish

Management declares victory over STELARA, guides 2026 growth above consensus.

Management exuded high confidence, explicitly correcting conservative analyst models for 2026 and providing granular details on pipeline catalysts that support an 'accelerated growth' narrative.

Red Flags

The separation of the Orthopaedics business introduces execution risk and potential stranded costs. While management projects margin expansion for the remaining entity, the complexity of spinning off a large, capital-intensive unit could lead to operational distractions. The 18-24 month timeline is lengthy, and the commitment to a tax-free spin-off limits strategic alternatives.

While Innovative Medicine growth is strong, the decline in STELARA (-42%) represents a significant revenue headwind that is only partially offset. The reliance on new launches like TREMFYA and Inlexo to fill this gap creates execution risk. Furthermore, the 75% share of STELARA sales in IBD that management hopes to capture with TREMFYA is a high bar to clear.

MedTech margins declined year-over-year from 24.1% to 21.0%, driven by macroeconomic factors and cost of products sold. While management attributes this to specific items like the Shockwave step-up, persistent margin pressure in a high-inflation environment could dampen profitability if pricing power is limited.

The effective tax rate increased significantly to 31.2% in Q3 from 19.3% in the prior year, primarily due to the remeasurement of deferred tax balances. While management guided for a 17.5%-18% rate for the full year, the volatility in tax rates introduces uncertainty to net earnings predictions.

Management noted a 'one-time reserve adjustment' in the Surgical business that aided growth, partially offset by headwinds in Energy and China VBP. The use of reserve adjustments to bolster results, even if immaterial, can be viewed as a quality of earnings concern by conservative investors.

Macro Insights

Regulatory Policy: Management acknowledged the 'One Big Beautiful Bill Act' which increased the effective tax rate in Q3 due to deferred tax remeasurement, creating a near-term headwind.

Healthcare Policy: Part D redesign and China VBP (Volume-Based Procurement) were cited as specific headwinds impacting growth in prostate cancer and surgical portfolios.

Manufacturing: J&J is committing $55 billion to U.S. manufacturing over the next four years, aligning with administration priorities to strengthen domestic supply chains.

Currency: The U.S. Dollar remained relatively flat against the Euro, resulting in minimal FX impact compared to prior guidance assumptions.